Media release - Roche

Media release
Basel, 19 October 2005
Roche continues to post strong growth through third quarter
Roche Group
• High growth rate of 17%* maintained in third quarter despite expiry of US Rocephin patent
• Group sales for first nine months up 17% (+16% in Swiss francs)
• Acquisition of GlycArt completed
Pharmaceuticals Division
• Sales growth remains strong at 22% (+20% in Swiss francs) — sales advance more than three
times as fast as the market
• Strong demand for cancer medicines; sales of Avastin already passed billion-franc mark;
Tarceva launched in Europe
• Tamiflu sales show further significant growth, driven by orders for pandemic readiness
supplies
• Bonviva launches under way in Europe
• MabThera/Rituxan filed in US and EU for rheumatoid arthritis
• Compelling data from several large clinical trials show Herceptin effective in early-stage
HER2-positive breast cancer
Diagnostics Division
• Sales growth in the third quarter accelerates by 2 percentage points to 6%
• Nine-month sales up 4% (+4% in Swiss francs)
• Molecular diagnostics, immunodiagnostics and diabetes care businesses post solid gains
• Innovative new diabetes management products successfully launched in all major markets
• World’s largest manufacturing facility for PCR-based products opened in Branchburg (USA)
* Unless otherwise stated, all percentage changes are period-over-period changes and are based on results in local
currencies.
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Corporate Communications Tel. 061 - 688 8888
Fax 061 - 688 2775
http://www.roche.com

Commenting on the Group’s performance in the first nine months of 2005, Roche Chairman and
CEO Franz B. Humer said, ‘Roche posted significant double-digit gains in the third quarter,
maintaining the strong sales growth of the first half-year. Our Pharmaceuticals Division gained
additional market share, with all major products contributing to this strong performance,
particularly our new cancer medicines. Roche Diagnostics has now rolled out its new Accu-Chek
products in all major markets, enhancing its competitive diabetes management portfolio. This
helped accelerate divisional sales growth in the third quarter.’
Roche Group
2005 2004 % Change
Sales from January to
September 1 mCHF mCHF in CHF in local currencies
Pharmaceuticals Division 19,434 16,132 +20 +22
Roche 12,169 10,523 +16 +16
Genentech 4,632 3,287 +41 +45
Chugai 2,633 2,322 +13 +15
Diagnostics Division 6,008 5,763 +4 +4
Roche Group 25,442 21,895 +16 +17
1 See attachment to this release for details on quarterly sales growth.
Roche posted sales of 25.4 billion Swiss francs in the first nine months of 2005, an increase of 17%
(+16% in Swiss francs; +20% in US dollars) over the same period last year. The Group thus
maintained the high growth rates reported for the first half-year. Nine-month sales in the
Pharmaceuticals Division increased 22% (+20% in Swiss francs), more than three times as fast as
the global market. The Diagnostics Division maintained its leading market position with sales
growth of 4% (+4% in Swiss francs).
The GlycArt acquisition, completed in July, has strengthened Roche’s expertise in therapeutic
antibody research and added new, cutting-edge technologies and products to Roche’s R&D
organisation and pipeline. In September Roche was reselected as an index component of the Dow
Jones Sustainability World Indexes (DJSI World) and Dow Jones STOXX Sustainability Indexes
(DJSI STOXX). In addition, Roche again met the FTSE4Good criteria, and thus continues to be a
member of the FTSE4Good Index series.
2

Pharmaceuticals Division
The Pharmaceuticals Division achieved impressive growth in the first nine months of 2005, with
sales up 22% in local currencies (+20% in Swiss francs; +24% in US dollars). Regional sales growth
significantly outpaced the market average in each of the division’s major markets: North America,
Europe and Japan. Growth was driven by continued strong demand for the division’s oncology
products. The anti-influenza drug Tamiflu, which a number of governments are stockpiling as part
of pandemic readiness programmes, also contributed to growth.
Oncology – continued strong sales growth
The division’s oncology portfolio achieved an outstanding growth of 37%, reinforcing Roche’s
position as the world’s leading provider of cancer medications.
Significant Improvements in Survival from Cancer Therapies
Therapy Disease / Indication Benefit
Avastin Metastatic Colorectal Cancer 30% increase in median overall
survival (Avastin+IFL
chemotherapy vs. IFL)
Herceptin
HER2-positive Metastatic
Breast Cancer
37% increase in median overall
survival (Herceptin+docetaxel
vs. docetaxel)
MabThera
Aggressive Non-Hodgkin-
Lymphoma
22% increase in 5-year overall
survival (MabThera+CHOP
chemotherapy vs. CHOP)
Tarceva
Advanced Non-Small Cell
Lung Cancer
43% increase in median overall
survival (Tarceva vs. placebo)
Xeloda Metastatic Breast Cancer 26% increase in median overall
survival (Xeloda+docetaxel vs.
docetaxel)
Worldwide sales of Avastin, a new breakthrough in cancer therapy, totalled 1.1 billion Swiss francs.
Indicated for the first-line treatment of patients with advanced colorectal cancer, Avastin is being
steadily rolled out in Europe and other countries. Recent phase III results have revealed Avastin’s
benefits in other tumour types; for example, a survival advantage with the drug has been seen both
in advanced non-small cell lung cancer and in metastatic breast cancer. Regulatory filings for these
new indications are planned for next year.
3

Sales of MabThera/Rituxan, for non-Hodgkin’s lymphoma (NHL), increased 22%, putting total
nine-month sales over the 3-billion-franc mark. This strong growth was driven by the steady rise in
prescriptions of the drug for indolent and aggressive NHL in Europe. During the third quarter
Genentech and Biogen Idec submitted a filing to the FDA for use in aggressive NHL. Roche intends
to submit a marketing application to the European authorities later this year for MabThera as
maintenance therapy in indolent NHL.
Herceptin, the only targeted treatment for HER2-positive breast cancer, posted significant sales
growth in all key markets (+38%). Four large-scale phase III trials investigating Herceptin in
patients with early-stage HER2-positive breast cancer have shown that adding Herceptin to
chemotherapy significantly reduces the risk of cancer recurrence in this population. Roche plans to
file for this new indication early next year.
Xeloda sales achieved strong worldwide growth of 47%. Sales advanced impressively both in the
United States (+64%) and in Europe/Rest of World (+39%), fuelled by recent US and EU approvals
for the use of Xeloda for the adjuvant (post surgery) treatment of colon cancer.
Sales of Tarceva, a novel targeted drug for advanced non-small cell lung cancer, reached 234 million
Swiss francs in the United States after just 11 months on the US market. Tarceva received approval
for this indication in the European Union in September, and the market roll-out there is already
under way. In addition, the FDA has voted in favour of recommending approval of Tarceva for the
treatment of advanced pancreatic cancer in previously untreated patients. A filing for the pancreatic
cancer indication was recently submitted to EU regulators.
Anemia — leadership maintained
Combined sales of NeoRecormon and Epogin were up 7% with growth seen in both the renal and
oncology indication. NeoRecormon sales for cancer-related anemia are expected to grow steadily,
helped by continued uptake of the new once weekly pre-filled syringe. Sales will also be
strengthened by a recent update of the product label, as a result of which NeoRecormon is now also
indicated for the correction of anemia in patients with solid and lymphoid tumours receiving any
form of chemotherapy.
Transplantation — CellCept number one worldwide
Thanks to strong, double-digit sales growth (+18%), CellCept remained the world’s top-selling
branded immunosuppressant for use in transplantation. Sales were up by double digits in the
United States, Europe and Japan.
4

Virology — Tamiflu sales surge forward
Worldwide sales of Tamiflu rose to 859 million Swiss francs, mainly as a result of increased orders
for pandemic readiness supplies. Roche has donated 3 million packs of Tamiflu to the World
Health Organisation (WHO) for use as a rapid response stockpile in the event of an outbreak of a
pandemic strain of influenza. The Group has already significantly expanded its Tamiflu production
capacity several times, and Roche will continue to take action, both on its own and with a
significant number of suppliers, to increase production capacity for Tamiflu to meet seasonal and
pandemic needs.
Sales of Pegasys, the market-leading pegylated interferon for hepatitis C, showed double-digit
growth (+17%), with demand running especially strong in Europe/Rest of World (+24%) and
Japan (+37%). Sales were driven primarily by three new indications approved over the course of
this year: use in patients co-infected with hepatitis C and HIV, treatment of hepatitis B and
treatment of hepatitis C in patients with normal liver enzymes. Pegasys is already approved for
hepatitis B in over 50 countries — including the United States, the European Union and China. A
Japanese filing for Pegasys plus Copegus in hepatitis C has been granted priority review status.
Sales of the anti-HIV medicine Fuzeon were up significantly for the period, rising 49% to 178
million Swiss francs. This reflects the continued flow of impressive new efficacy data in treatmentexperienced
patients with HIV/AIDS.
Other major products — Bonviva approved for once monthly oral use in Europe
Bonviva/Boniva, the first once monthly oral bisphosphonate for the treatment and prevention of
osteoporosis, was recently approved in the European Union and Switzerland. In the United States,
where the product has been available since April, patient acceptance has been good, both among
previously untreated women and among women switching to Boniva from other treatments.
Global sales of Xenical grew 4%. The labelling for Xenical has been expanded to include clinical
trial data on the use of the product in obese adolescents, making it the first and only weight loss
medication in the United States and Europe to contain such information in the label.
GlaxoSmithKline has filed with the FDA for approval of an OTC formulation of orlistat.
Total Rocephin sales declined in line with expectations (-21%) following expiry of the US patent in
July. Third-quarter sales were down more than 50% from the year before.
5

Major development activities in the third quarter — first filings in rheumatoid arthritis
The US and EU filings for MabThera/Rituxan in its first rheumatoid arthritis indication represent a
significant milestone for the product. The filings are for use in patients who have failed to respond
adequately to current biologic therapies — the rheumatoid arthritis patients most difficult to treat.
Positive outcomes have also been seen in clinical trials with patients who had previously failed
treatment with one or more disease-modifying anti-rheumatic drugs.
Development of Actemra (formerly known as MRA) for rheumatoid arthritis is progressing well.
Data from a phase III programme in Japan will be presented later this year, and patient recruitment
for international phase III trials in rheumatoid arthritis is proceeding as planned.
Diagnostics Division
Sales growth in line with the market
In the first nine months of 2005 Roche Diagnostics posted sales of 6 billion Swiss francs, an increase
of 4% (+4% in Swiss francs; +7% in US dollars) over the year-earlier period. Third-quarter sales
growth accelerated to 6%. Molecular diagnostics, immunodiagnostics and diabetes care continue to
be the main contributors of growth. Sales in Japan showed a high single-digit increase, while growth
in the EMEA region (Europe, Middle East, Africa) was in the mid single digits, slightly above the
market average. The division posted double-digit gains in Asia–Pacific and Iberia/Latin America,
outpacing the market in both regions. Substantial investments were made in ongoing product
launches in the United States, where the new Accu-Chek Aviva device has been very well received
by the market.
Diabetes Care – new portfolio rolled out
Roche Diabetes Care posted sales growth of 4%. The global launch of Accu-Chek Aviva was
successfully completed. The new Accu-Chek Spirit insulin pump is now available in 21 countries
and accounts for 40% of all Roche insulin pump sales.
Near Patient Testing — strong growth in coagulation monitoring segment
Roche Near Patient Testing reported overall sales growth of 4%. In the coagulation business,
growth was well into the double digits, while the Cardiac Reader segment posted high single-digit
gains. The Roche Cardiac proBNP test was launched worldwide for use on the Cardiac Reader,
making it the first point-of-care NT proBNP assay for heart failure to reach the market. Cardiac
Reader placements were up 6% from the previous year, and during the first nine months the
10,000 th Cardiac Reader was manufactured. In the blood gas/electrolyte analyser segment, Roche
6

Diagnostics placed 65% more Roche Omni S instruments than during the same period last year.
Centralized Diagnostics — growth above the market
Sales by Roche Centralized Diagnostics increased 5% in a market estimated to be growing at a rate
of 3%. This dynamic performance was driven mainly by a record number of placements of Cobas
Integra and Elecsys systems (+23% and +29%, respectively). Thanks to Elecsys proBNP, Roche
Diagnostics is now the number-one supplier of cardiac biomarker assays. This brings Roche
another step closer to its goal of achieving market leadership in immunodiagnostics.
Molecular Diagnostics — market leadership maintained
Roche Molecular Diagnostics maintained its leading market share of over 40%, as sales rose 6%.
This business area’s largest segments, virology and blood screening, continued to grow in line with
the market. The new automated virology systems and real-time PCR-based tests have been well
received in European markets, where they were recently launched. In the blood screening segment,
Roche received FDA clearance for a new hepatitis B test for screening organ and tissue donations.
Roche’s established blood screening tests remain the market leaders, providing a strong platform
for future launches of the highly automated blood screening systems currently in development at
Roche.
At its Branchburg site (USA), Roche opened the world’s largest PCR production facility in July to
meet the rising demand for its PCR-based products.
Applied Science — market position stabilised
Roche Applied Science consolidated its position (+1%) in an increasingly competitive market. The
launch of a new ultra-fast nanotechnology-based DNA sequencing system at the end of September
and the new LightCycler 480 DNA amplification system in early October will significantly reinforce
Roche Applied Science’s position as a provider of superior bioanalytical systems.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused
healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative
products and services for the early detection, prevention, diagnosis and treatment of disease, the
Group contributes on a broad range of fronts to improving people’s health and quality of life.
Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and
transplantation and a market leader in virology. Roche employs roughly 65,000 people in 150
countries and has R&D agreements and strategic alliances with numerous partners, including
7

majority ownership interests in Genentech and Chugai. Additional information about the Roche
Group is available on the Internet at www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Additional information
- Media release with sales tables: www.roche.com/med-cor-2005-10-19
- Full-year report for 2005: 1 February 2006
Roche Group Media Office
Phone: +41 61 688 8888 / E-Mail: basel.mediaoffice@roche.com
- Baschi Dürr
- Alexander Klauser
- Daniel Piller (Head of Roche Group Media Office)
- Katja Prowald (Head of Science Communications)
- Martina Rupp
Disclaimer
This release contains certain forward-looking statements. These forward-looking statements may be
identified by words such as “believes”, “expects”, “anticipates”, “projects”, “intends”, “should”,
“seeks”, “estimates”, “future” or similar expressions or by discussion of strategy, goals, plans or
intentions. Various factors may cause actual results to differ materially in the future from those
reflected in forward-looking statements contained in this presentation among others: (1) pricing
and product initiatives of competitors; (2) legislative and regulatory developments and economic
conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market;
(4) fluctuations in currency exchange rates and general financial market conditions; (5)
uncertainties in the discovery, development or marketing of new products or new uses of existing
products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of
or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of
key executives or other employees; and (11) adverse publicity or news coverage.
8

1. Sales January to September 2005 and 2004
2005 2004 % change
January – September CHF m CHF m In CHF In local
currencies
Pharmaceuticals Division 19,434 16,132 +20 +22
Roche Pharmaceuticals 12,169 10,523 +16 +16
Genentech 4,632 3,287 +41 +45
Chugai 2,633 2,322 +13 +15
Diagnostics Division 6,008 5,763 +4 +4
Roche Group 25,442 21,895 +16 +17
2. Quarterly local sales growth by Division in 2004 and 2005
Q4 2004
vs. Q4 2003
Q1 2005
vs. Q1 2004
Q2 2005
vs. Q2 2004
Q3 2005
vs. Q3 2004
Pharmaceuticals Division +5 +22 +21 +21
Roche Pharmaceuticals -2 +11 +18 +17
Genentech +48 +54 +41 +42
Chugai -8 +32 +8 +7
Diagnostics Division +6 +4 +4 +6
Roche Group +6 +17 +17 +17
3. Quarterly sales by Division in 2004 and 2005
CHF millions Q3 2004 Q4 2004 Q1 2005 Q2 2005 Q3 2005
Pharmaceuticals Division 5,485 5,563 6,155 6,497 6,782
Roche Pharmaceuticals 3,483 3,447 3,859 4,119 4,191
Genentech 1,235 1,235 1,341 1,526 1,765
Chugai 767 881 955 852 826
Diagnostics Division 1,884 2,064 1,935 2,035 2,038
Roche Group 7,369 7,627 8,090 8,532 8,820

4. Top 20 Pharmaceuticals Division product sales 1 and local growth 2 in first nine months of 2005:
US, Japan and Europe/Rest of World
Total US Japan Europe/RoW
CHF m % CHF m % CHF m % CHF m %
MabThera/Rituxan 3,001 22% 1,725 16% 142 6% 1,134 35%
Neo Recormon/Epogin 1,650 7% - - 580 3% 1,070 9%
Herceptin 1,442 38% 610 41% 88 17% 744 38%
Cellcept 1,241 18% 577 23% 20 21% 644 14%
Avastin 1,093 148% 949 118% - - 144 2935%
Pegasys 1,030 17% 357 5% 65 37% 608 24%
Tamiflu 859 263% 183 297% 265 223% 411 279%
Rocephin 766 -21% 442 -23% 44 20% 280 -21%
Xeloda 568 47% 214 64% 22 35% 332 39%
Xenical 474 4% 73 -1% - - 401 5%
Kytril 365 11% 147 14% 98 11% 120 7%
Nutropin/Protropin 348 7% 339 7% - - 9 -5%
Copegus 320 10% 149 -10% - - 171 36%
Pulmozyme 286 15% 169 20% - - 117 7%
Cymevene/Valcyte 285 17% 145 8% - - 140 28%
Xolair 285 82% 285 82% - - - -
Neutrogin 266 14% - - 266 14% - -
Tarceva 246 - 234 - - - 12 -
Dilatrend 246 -15% - - - - 246 -15%
Activase/TNKase 223 8% 197 9% - - 26 -3%
1
2
New products not covered in Top 20
Fuzeon 178 49% 89 22% - - 89 95%
Raptiva 87 87% 87 87% - - - -
Evista 69 201% - - 69 201% - -
Renagel 41 26% - - 41 26% - -
Boniva 35 - 34 - - - 1 -
Roche Pharmaceuticals, Genentech and Chugai combined
versus first nine months of 2004

5. Top 20 Pharmaceuticals Division quarterly local product sales growth 1 in 2004 and 2005
Q4 2004
vs. Q4 2003
Q1 2005
vs. Q1 2004
Q2 2005
vs. Q2 2004
Q3 2005
vs. Q3 2004
MabThera/Rituxan 20% 24% 23% 18%
NeoRecormon/Epogin 1% 7% 8% 6%
Herceptin 25% 23% 31% 57%
Cellcept 3% 4% 25% 28%
Avastin - 476% 112% 107%
Pegasys 24% 15% 22% 15%
Tamiflu -69% 302% 707% 148%
Rocephin -5% -6% -5% -54%
Xeloda 39% 48% 50% 44%
Xenical -5% 4% 0% 9%
Kytril 11% 0% 18% 14%
Nutropin/Protropin 10% 7% 10% 3%
Copegus 13% 5% 15% 9%
Pulmozyme 3% 10% 20% 15%
Cymevene/Valcyte 26% 2% 29% 22%
Xolair 230% 128% 88% 51%
Neutrogin 7% 9% 13% 20%
Tarceva - - - -
Dilatrend -27% -19% -13% -12%
Activase/TNKase 5% 12% 3% 9%
1
Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth 1 US in 2004 and 2005
Q4 2004
vs. Q4 2003
Q1 2005
vs. Q1 2004
Q2 2005
vs. Q2 2004
Q3 2005
vs. Q3 2004
MabThera/Rituxan 8% 19% 16% 14%
NeoRecormon/Epogin - - - -
Herceptin 18% 19% 29% 70%
Cellcept -7% -8% 33% 52%
Avastin - 432% 85% 78%
Pegasys -3% -9% 19% 9%
Tamiflu -72% - 493% 132%
Rocephin 5% 1% 5% -75%
Xeloda 72% 74% 72% 51%
Xenical -37% -1% -14% 20%
Kytril 20% -9% 33% 20%
Nutropin/Protropin 11% 7% 10% 3%
Copegus -24% -28% 4% -2%
Pulmozyme 5% 16% 28% 17%
Cymevene/Valcyte 35% -9% 20% 17%
Xolair 230% 128% 88% 51%
Neutrogin - - - -
Tarceva - - - -
Dilatrend - - - -
Activase/TNKase 6% 14% 5% 10%
1
Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan 1 in 2004 and 2005
Q4 2004
vs. Q4 2003
Q1 2005
vs. Q1 2004
Q2 2005
vs. Q2 2004
Q3 2005
vs. Q3 2004
MabThera/Rituxan 15% 7% 11% 1%
NeoRecormon/Epogin 0% 2% 5% 2%
Herceptin 18% 19% 18% 15%
Cellcept 20% 20% 26% 18%
Avastin - - - -
Pegasys 1190% 135% 33% 4%
Tamiflu -87% 209% - -
Rocephin 2% 33% 13% 17%
Xeloda 28% 41% 38% 27%
Xenical - - - -
Kytril 0% 14% 10% 10%
Nutropin/Protropin - - - -
Copegus - - - -
Pulmozyme - - - -
Cymevene/Valcyte - - - -
Xolair - - - -
Neutrogin 7% 9% 13% 20%
Tarceva - - - -
Dilatrend - - - -
Activase/TNKase - - - -
1
Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World 1 in 2004
and 2005
Q4 2004
vs. Q4 2003
Q1 2005
vs. Q1 2004
Q2 2005
vs. Q2 2004
Q3 2005
vs. Q3 2004
MabThera/Rituxan 51% 36% 39% 29%
NeoRecormon/Epogin 2% 10% 10% 9%
Herceptin 34% 26% 34% 51%
Cellcept 14% 14% 19% 9%
Avastin - - - 1755%
Pegasys 33% 29% 23% 20%
Tamiflu 103% 361% 654% 158%
Rocephin -22% -20% -22% -23%
Xeloda 23% 36% 39% 41%
Xenical 5% 5% 3% 7%
Kytril 9% 4% 10% 9%
Nutropin/Protropin 4% -5% -3% -6%
Copegus 120% 61% 29% 22%
Pulmozyme 1% 2% 10% 11%
Cymevene/Valcyte 15% 19% 39% 27%
Xolair - - - -
Neutrogin - - - -
Tarceva - - - -
Dilatrend -27% -19% -13% -12%
Activase/TNKase -5% -3% -11% 6%
1
Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales 1, 2 in 2004 and 2005
CHF millions Q3 2004 Q4 2004 Q1 2005 Q2 2005 Q3 2005
MabThera/Rituxan 877 877 929 1,015 1,057
NeoRecormon/Epogin 528 534 516 570 564
Herceptin 373 378 391 460 591
Cellcept 337 347 370 430 441
Avastin 235 238 260 347 486
Pegasys 296 299 325 355 350
Tamiflu 110 93 424 156 279
Rocephin 307 321 330 284 152
Xeloda 145 146 165 190 213
Xenical 145 137 147 165 162
Kytril 114 123 105 130 130
Nutropin/Protropin 110 113 110 122 116
Copegus 97 87 104 109 107
Pulmozyme 86 86 89 97 100
Cymevene/Valcyte 81 83 86 99 100
Xolair 68 73 81 100 104
Neutrogin 81 85 80 89 97
Tarceva - 17 57 88 101
Dilatrend 86 75 83 84 79
Activase/TNKase 76 64 67 72 84
New products not covered in Top 20
Fuzeon 43 47 50 66 62
Raptiva 23 22 28 31 28
Evista 6 15 16 25 28
Renagel 11 12 11 15 15
Boniva - - - 21 14
1
Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales 1 in US in 2004 and 2005
CHF millions Q3 2004 Q4 2004 Q1 2005 Q2 2005 Q3 2005
MabThera/Rituxan 531 514 540 573 612
NeoRecormon/Epogin - - - - -
Herceptin 159 149 153 186 271
Cellcept 147 157 152 200 225
Avastin 230 230 240 300 409
Pegasys 112 110 109 124 124
Tamiflu 47 42 30 44 109
Rocephin 191 207 208 180 54
Xeloda 55 56 60 71 83
Xenical 20 20 25 24 24
Kytril 46 52 39 54 54
Nutropin/Protropin 107 110 107 119 113
Copegus 53 40 43 53 53
Pulmozyme 50 51 52 57 60
Cymevene/Valcyte 44 47 43 49 53
Xolair 68 73 81 100 104
Neutrogin - - - - -
Tarceva - 17 56 86 92
Dilatrend - - - - -
Activase/TNKase 67 56 60 64 73
New products not covered in Top 20
Fuzeon 25 28 26 29 34
Raptiva 23 22 28 31 28
Evista - - - - -
Renagel - - - - -
Boniva - - - 21 13
1
Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales 1 in Japan in 2004 and 2005
CHF millions Q3 2004 Q4 2004 Q1 2005 Q2 2005 Q3 2005
MabThera/Rituxan 49 58 40 52 50
NeoRecormon/Epogin 199 220 168 209 203
Herceptin 28 31 25 31 32
Cellcept 6 7 6 7 7
Avastin - - - - -
Pegasys 22 25 19 23 23
Tamiflu - 15 260 3 2
Rocephin 12 16 15 15 14
Xeloda 6 8 6 8 8
Xenical - - - - -
Kytril 31 37 28 35 35
Nutropin/Protropin - - - - -
Copegus - - - - -
Pulmozyme - - - - -
Cymevene/Valcyte - - - - -
Xolair - - - - -
Neutrogin 81 85 80 89 97
Tarceva - - - - -
Dilatrend - - - - -
Activase/TNKase - - - - -
New products not covered in Top 20
Fuzeon - - - - -
Raptiva - - - - -
Evista 6 15 16 25 28
Renagel 11 12 11 15 15
Boniva - - - - -
1
Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World 1 in 2004 and 2005
CHF millions Q3 2004 Q4 2004 Q1 2005 Q2 2005 Q3 2005
MabThera/Rituxan 297 305 349 390 395
NeoRecormon/Epogin 329 314 348 361 361
Herceptin 186 198 213 243 288
Cellcept 184 183 212 223 209
Avastin 5 8 20 47 77
Pegasys 162 164 197 208 203
Tamiflu 63 36 134 109 168
Rocephin 104 98 107 89 84
Xeloda 84 82 99 111 122
Xenical 125 117 122 141 138
Kytril 37 34 38 41 41
Nutropin/Protropin 3 3 3 3 3
Copegus 44 47 61 56 54
Pulmozyme 36 35 37 40 40
Cymevene/Valcyte 37 36 43 50 47
Xolair - - - - -
Neutrogin - - - - -
Tarceva - - 1 2 9
Dilatrend 86 75 83 84 79
Activase/TNKase 9 8 7 8 11
New products not covered in Top 20
Fuzeon 18 19 24 37 28
Raptiva - - - - -
Evista - - - - -
Renagel - - - - -
Boniva - - - - 1
1
Roche Pharmaceuticals